Thursday, August 10, 2017

Novo Nordisk defends U.S. diabetes drug pricing

COPENHAGEN (Reuters) - Danish diabetes drug maker Novo Nordisk on Friday defended its pricing of diabetes drugs after facing allegations of pricing collusion by U.S. senators....

Stay connected

7,421FansLike
3,010FollowersFollow